Pliant Therapeutics, Inc.
PLRXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PLRX Earnings Report
EPS Est: $-0.33 | FQ end 2026-06
How PLRX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PLN-74809 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pliant Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Pliant Therapeutics, Inc.'s (PLRX) pipeline across Phase 2. Its lead program is PLN-74809 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pliant Therapeutics, Inc.'s next FDA catalyst?→
Pliant Therapeutics, Inc.'s (PLRX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PLRX biotech catalysts?→
Add PLRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pliant Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.